ESR1 and breast carcinoma: Thus, for ERα-positive BRCA1/2-related BC, chemoprevention, oophorectomy, and adjuvant treatment with selective estrogen receptor modulators or aromatase inhibitors to reduce risk of contralateral breast cancer are promising options.